Urolog. pro Praxi, 2001; 5: 197-200

Benigní hyperplázie prostaty a terapie alfablokátory

Miroslav Hanuš

Keywords: BPH, pharmacotherapy, alfa-blockers.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hanuš M. Benigní hyperplázie prostaty a terapie alfablokátory. Urol. praxi. 2001;2(5):197-200.

Hyperplázie prostaty (BPH - nezhoubné zvětšení žlázy) je typickým onemocněním probíhajícím v závislosti na věku. Histologické změny lze prokázat od 40 let výše, většinou však mnohem dříve. Nejsou ale provázeny žádnou symptomatologií. U mužů od 50 let věku se s příznaky obstrukce mikce změněnou prostatou setkáváme častěji a histologicky je hyperplázie prokazatelná prakticky vždy. Asi polovina mužů nad 60 let má již výrazné mikční obtíže, z nich opět asi polovina s nimi přichází k lékaři. U těchto pacientů je obvykle zapotřebí, po diagnostickém upřesnění, zavést některou z léčebných modalit. Článek pojednává o nejčastějsí farmakoterapii BPH použitím alfablokátorů.

Benign Prostatic Hyperplasia (BPH) and Therapy with Alfa-blockers

Hyperplasia of the prostate (benign enlargement of the gland) is a common disease and it-s clinical course depends on the age. Histological ch anges can be detected in men from the age of 40 and above, but sometimes even earlier. These changes are not usually accompanied by any symptoms. In men in their fifties, signs of obstruction of micturition, due to a changed prostatic gland, are easily found and hyperplasia is present in virtually all the histologic specimens. About half of the men over 60 years of age suffer from difficulties in micturition, and half of those affected seek medical advice. After proper diagnostic evaluation, these patients may then be suitable candidates for initiation into one of the treatment modalities. In BPH management the most common pharmacotherapy used is the use of alfa-blockers and the reason for this is outlined in this article.

Download citation

References

  1. Arnold, E. P. (1996): Flow rate and post-voidal issues in Kirby R, McConnell J D, Fitzpatrick J M, Roehrborn C G, P. Boyle Textbook of Benign Prostatic Hyperplasia, ISIS, Oxford, 566 pp.
  2. Caine, M., Raz, S., Ziegler, M. (1975): Adrenergic a cholinergic receptors in the human prostatic capsule and bladder neck. Br. J. Urol., 47: 193-202. Go to original source... Go to PubMed...
  3. Caine, M. (1986): The present role of alpha adrenergic blockers in the treatment of benign prostatic hyperplasia. J. Urol., 136: 1-4. Go to original source... Go to PubMed...
  4. Debruyne, F. M. J., van der Poel, H. G. (1999): Clinical experience in Europe with uroselective ?1-antagonist. Eur. Urol., 36 (suppl. 1): 54-58. Go to original source... Go to PubMed...
  5. Dorflinger, T., Bruskewitz, R. C., Jensen, K. M. E. et al. (1986): Predictive value of low maximum flow rate in benign prostatic hyperplasia. Urology, 27: 569-573. Go to original source... Go to PubMed...
  6. Ford, A. P. D. W., Daniels, D. V., Chang, D. J. et al. (1997): Pharmacological pleiotropism of the human recombinant ?1A-adrenoceptor: implications for ?1adrenoceptor classification, B. J. Pharm., 121: 1127-1135. Go to original source... Go to PubMed...
  7. Kenny, B. A., Naylor, A. M., Wyllie, M. G.: Prostatic adrenoceptors in Kirby, R., McConnell, J. D., Fitzpatrick, J. M., Roehrborn, C. G., Boyle, P. (1996): Textbook of Benign Prostatic Hyperplasia, ISIS, Oxford, 566 pp.
  8. Lepor, H., Shapiro, E. (1984): Characterisation of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J. Urol., 132: 1226-1229. Go to original source... Go to PubMed...
  9. (1999) Lower urinary tract symptoms. Proceedings of an Expert Meeting, London, 14 December, 21 pp.
  10. Rosier, P. F. W. M., Rollema, H. J., van der Beek, C., Janknegt, R. A. (1992): Diagnosis of, ,prostatism" relation between symptoms and urodynamic evaluation of obstruction and bladder function. Neurourol. Urodyn., 11: 399-400.
  11. Shapiro, E., Becich, M. J., Hartanto, V. et al. (1992): The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostatic hypeplasia. J. Urol., 147: 1293-1297. Go to original source... Go to PubMed...
  12. Shapiro, E., Lepor, H. (1986): Alpha 2adrenergic receptors in hyperplastic human prostate: identification and characterization using /3H/ rauwolscine. J. Urol., 135: 1038-1043. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.